223 related articles for article (PubMed ID: 34840594)
1. Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma.
Tang X; Miao Y; Wang J; Cai T; Yang L; Mi D
Comput Math Methods Med; 2021; 2021():1205029. PubMed ID: 34840594
[TBL] [Abstract][Full Text] [Related]
2. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma.
Huang DP; Liao MM; Tong JJ; Yuan WQ; Peng DT; Lai JP; Zeng YH; Qiu YJ; Tong GD
Aging (Albany NY); 2021 Nov; 13(22):24621-24639. PubMed ID: 34799469
[TBL] [Abstract][Full Text] [Related]
3. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
4. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
6. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
7. Computational identification of mutator-derived lncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer.
Bao S; Zhao H; Yuan J; Fan D; Zhang Z; Su J; Zhou M
Brief Bioinform; 2020 Sep; 21(5):1742-1755. PubMed ID: 31665214
[TBL] [Abstract][Full Text] [Related]
8. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
9. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
10. Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks.
Yu X; Zhang J; Yang R; Li C
Biomed Res Int; 2020; 2020():8579651. PubMed ID: 33299877
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
13. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
15. 15-lncRNA-Based Classifier-Clinicopathologic Nomogram Improves the Prediction of Recurrence in Patients with Hepatocellular Carcinoma.
Zhang Q; Ning G; Jiang H; Huang Y; Piao J; Chen Z; Tan X; Zhang J; Liu G
Dis Markers; 2020; 2020():9180732. PubMed ID: 33520012
[TBL] [Abstract][Full Text] [Related]
16. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
17. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer.
Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L
Front Immunol; 2022; 13():929846. PubMed ID: 35990656
[TBL] [Abstract][Full Text] [Related]
18. A computational prognostic model of lncRNA signature for clear cell renal cell carcinoma with genome instability.
Cui T; Guo J; Sun Z
Expert Rev Mol Diagn; 2022 Feb; 22(2):213-222. PubMed ID: 34871123
[TBL] [Abstract][Full Text] [Related]
19. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature.
Wu H; Zhang ZY; Zhang Z; Xiao XY; Gao SL; Lu C; Zuo L; Zhang LF
Bioengineered; 2021 Dec; 12(1):1725-1738. PubMed ID: 33955803
[TBL] [Abstract][Full Text] [Related]
20. Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC.
Huang K; Lu Z; Li L; Peng G; Zhou W; Ye Q
Hum Cell; 2021 Nov; 34(6):1830-1842. PubMed ID: 34487338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
